Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1020748-57-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of moxetumomab pasudotox during breastfeeding. Because moxetumomab is a large protein molecule with a molecular weight of about 63,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Pasudotox is a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential anti-cancer activity that may enter milk. Until more data become available, moxetumomab pasudotox should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Moxetumomab Pasudotox
CAS Registry Number
1020748-57-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.[Clin Cancer Res. 2011]Review Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.Kreitman RJ, Pastan I. Clin Cancer Res. 2011 Oct 15; 17(20):6398-405.
- Review Moxetumomab Pasudotox: First Global Approval.[Drugs. 2018]Review Moxetumomab Pasudotox: First Global Approval.Dhillon S. Drugs. 2018 Nov; 78(16):1763-1767.
- An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.[Leuk Res. 2014]An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Bera TK, Onda M, Kreitman RJ, Pastan I. Leuk Res. 2014 Oct; 38(10):1224-9. Epub 2014 Jul 5.
- Immunotoxins with decreased immunogenicity and improved activity.[Leuk Lymphoma. 2011]Immunotoxins with decreased immunogenicity and improved activity.Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Leuk Lymphoma. 2011 Jun; 52 Suppl 2(Suppl 2):87-90. Epub 2011 Apr 19.
- Review Galcanezumab.[Drugs and Lactation Database (...]Review Galcanezumab.. Drugs and Lactation Database (LactMed®). 2006
- Moxetumomab Pasudotox - Drugs and Lactation Database (LactMed®)Moxetumomab Pasudotox - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...